The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane

Fertility and Sterility

Volumn 69, Issue 5, 1998, Pages 883-888

  Ylikorkala, Olavi ^a,b   Cacciatore, Bruno ^a   Paakkari, Ilari ^a   Tikkanen, Matti J ^a   Viinikka, Lasse ^a   Toivonen, Juhani ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Endothelial cell function; Oral HRT; Transdermal HRT

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 2,3 DINORTHROMBOXANE B2; ENDOTHELIN 1; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; FOLLITROPIN; NITRATE; NITRIC OXIDE; NORETHISTERONE ACETATE; PROSTACYCLIN; THROMBOXANE A2; TRISEQUENS;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MIXTURE; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TABLET; TRANSDERMAL DRUG ADMINISTRATION; VASODILATATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ENDOTHELIN-1; EPOPROSTENOL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NITRIC OXIDE; NORETHINDRONE; POSTMENOPAUSE; PROSPECTIVE STUDIES; THROMBOXANES;

EID: 0032079436     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00028-4     Document Type: Article

References (34)

1. 1. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
2. 2. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-7.
3. 3. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an update analysis. Br J Obstet Gynaecol 1990;97:1080-6.
4. 4. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
5. 5. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
6. 6. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation in transdermal oestradiol and time since menopause. Lancet 1991;338:839-42.
7. 7. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-6.
8. 8. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91.
9. 9. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Canon RO III. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75:264-8.
10. 10. Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, et al. Estrogen increases endothelial nitric oxide by a receptor mediated system. Biochem Biophys Res Commun 1995;214:847-55.
11. 11. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEES Lett 1995;360:291-3.
12. 12. Ylikorkala O, Hirvonen E, Saure A, Viinikka L. Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. Prostaglandins 1990;39: 33-7.
13. 13. Foidart JM, Dombrowitz N, de Lieniere B. Urinary excretion of prostacyclin and thromboxane metabolites in postmenopausal women treated with percutaneous estradiol (Oestrogel®) or conjugated estrogens (Premarin®). In: Dusitsin N, Notelovitz M, eds. Physiological hormone replacement therapy. Carnforth (UK): Parthenon Publishing Company, 1990:99-107.
14. 14. Viinikka L, Orpana A, Puolakka J, Pyörälä T, Ylikorkala O. Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2. Obstet Gynecol 1997;89:104-7.
15. 15. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17β-Estradiol stimulates prostacyclin, but not endothelin-1 production in human vascular endothelial cells. J Clin Endocrinol Metab 1995;80: 1832-6.
16. 16. Ylikorkala O, Orpana A, Puolakka J, Pyörälä T, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995;80:3384-7.
17. 17. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin-1 levels. Ann Intern Med 1993;118:429-32.
18. 18. Wilcox JG, Stanczyk FZ, Hatch IE, Lobo RA. Endothelin levels decrease after oral and normal estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril 1997;67:273-7.
19. 19. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31.
20. 20. Orpana A, Avela K, Viinikka L, Ylikorkala O. The calcium-dependent nitric oxide production of human vascular endothelial cells in preeclampsia. Am J Obstet Gynecol 1996;174:1056-60.
21. 21. National Academy of Sciences Committee on Nitrate and Alternative Curing Agents in Food. The health effects of nitrate, nitrite and N-nitroso compounds. Washington, DC: National Academy Press, 1981.
22. 22. Ylikorkala O, Pekonen F, Viinikka L. Renal prostacyclin and thromboxane in normotensive and preeclamptic pregnant women and their infants. J Clin Endocrinol Metab 1986;63:1307-12.
23. 23. Tulppala M, Viinikka L, Ylikorkala O. Prostacyclin and thromboxane production in habitual abortion: evidence of thromboxane dominance and prostacyclin deficiency. Lancet 1991;337:879-82.
24. 24. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
25. 25. Cicinelli E, Matteo G, Ignarro LJ, Falco N, Lograno M, Schonauer LM. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 1997; 67:63-6.
26. 26. Imthurn B, Roselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 1997;82:388-94.
27. 27. Kohno M, Yasunari K, Murakawa K, Yokokawa K, Horio T, Fukui T, et al. Plasma immunoreactive endothelin-1 in essential hypertension. Am J Med 1990;88:614-8.
28. 28. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, et al. Plasma endothelin-1 levels in hypertension and chronic renal failure. Hypertension 1990;15:493-6.
29. 29. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metabolism 1994;43:267-9.
30. 30. Steinleitner A, Stanczyk FZ, Levin JH, d'Ablaing G III, Vijod MA, Shahbazian VL, et al. Decreased in vitro production of 6-keto-prostaglandin F1a by uterine arteries from postmenopausal women. Am J Obstet Gynecol 1989;161:1677-81.
31. 31. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987;76:6-14.
32. 32. Lassila R, Seyberth HW, Haapanen A, Schweer H, Koskenvuo M, Laustiola KE. Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking. Br Med J 1988;297:955-7.
33. 33. Luotola H. Blood pressure and hemodynamics in postmenopausal women during estradiol-17β substitution. Ann Clin Res 1983; 15(suppl):1-121.
34. 34. Dallongeville J, Marecaux N, Isorez D, Zylberg G, Fruchart J-C, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995;118:123-33.